• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 3. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives

Introduction to 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine (CAS No: 230305-81-4)

3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical chemistry due to its unique structural properties and potential biological activities. The compound belongs to the class of pyrazolopyridine derivatives, which are known for their broad spectrum of pharmacological effects. The presence of a trifluoromethyl group in the molecule enhances its metabolic stability and binding affinity, making it a valuable scaffold for drug discovery.

The chemical structure of 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine consists of a fused ring system comprising a pyrazole ring and a pyridine ring, with the trifluoromethyl substituent attached to the pyrazole ring. This arrangement contributes to the compound's ability to interact with various biological targets, including enzymes and receptors. The trifluoromethyl group, in particular, is known to modulate the electronic properties of the molecule, influencing its reactivity and biological activity.

In recent years, there has been a growing interest in pyrazolopyridine derivatives as potential therapeutic agents. These compounds have shown promise in various preclinical studies, particularly in the treatment of inflammatory diseases, cancer, and neurological disorders. The structural features of 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine make it an attractive candidate for further investigation into its pharmacological properties.

One of the most compelling aspects of 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine is its potential as an intermediate in the synthesis of more complex pharmaceutical molecules. The pyrazolopyridine core can be modified in various ways to create derivatives with enhanced biological activity or improved pharmacokinetic profiles. Researchers have been exploring different synthetic pathways to functionalize this scaffold, leading to a diverse library of compounds that could serve as lead candidates for drug development.

The trifluoromethyl group is particularly noteworthy in this context. It is a common pharmacophore that enhances the binding affinity of small molecules to their targets. This group can also influence the metabolic stability of a compound, reducing the likelihood of rapid degradation in vivo. These properties make 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine a valuable building block for medicinal chemists seeking to develop novel therapeutics.

Recent studies have highlighted the potential of 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine in addressing unmet medical needs. For instance, researchers have investigated its activity against certain kinases involved in cancer progression. The compound has been shown to inhibit the activity of these enzymes, potentially leading to therapeutic benefits. Additionally, its ability to modulate inflammatory pathways has been explored in models of autoimmune diseases.

The synthesis of 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include condensation reactions between hydrazines and ketones or aldehydes, followed by functionalization with fluorinated intermediates. Advances in synthetic methodologies have enabled more efficient and scalable production processes for this compound.

The pharmacological evaluation of 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine has revealed several interesting properties. In vitro studies have demonstrated its ability to interact with various biological targets, including protein kinases and transcription factors. These interactions suggest potential therapeutic applications across multiple disease areas. Further preclinical studies are needed to fully characterize its safety profile and efficacy.

One area of active research is the development of trifluoromethylated heterocycles as antiviral agents. The unique electronic properties of trifluoromethylation can enhance the binding affinity of small molecules to viral enzymes or receptors. Preliminary data suggest that 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine may have inhibitory effects against certain viruses, making it a promising candidate for antiviral drug development.

The future prospects for 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine are bright, with ongoing research aimed at expanding its therapeutic applications. Collaborative efforts between academic institutions and pharmaceutical companies are likely to drive innovation in this field. As our understanding of molecular interactions continues to grow, compounds like 3-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine will play an increasingly important role in the development of novel treatments for human diseases.

• 1146011-20-2(3-methyl-6-(trifluoromethyl)-2H-indazole)
• 57631-05-7(3-(Trifluoromethyl)-1H-indazole)
• 120422-91-5(3-Methyl-1H-pyrazolo[4,3-c]pyridine)
• 503173-01-1(Pyrazolo[1,5-a]pyridine, 7-methyl-2-(trifluoromethyl)- (9CI))
• 945265-11-2(3-Methyl-5-(trifluoromethyl)-1H-indazole)
• 57631-11-5(5-Bromo-3-(trifluoromethyl)-1H-indazole)
• 57631-13-7(5-chloro-3-(trifluoromethyl)-1H-indazole)
• 340809-52-1(6-(Trifluoromethyl)-1H-pyrazolo[4,3-C]pyridine)
• 863637-27-8(2H-Indazole, 3-(trifluoromethyl)-)
• 1256792-31-0(4-(Trifluoromethyl)-1H-pyrazolo[4,3-c]pyridine)